<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages>en</availableLanguages>
  <rcn>239584</rcn>
  <id>101071749</id>
  <acronym>CanceRusolution</acronym>
  <teaser>R-nuucell is developing a new drug to treat Triple Negative Breast Cancer (TNBC) for which there is not any specific and efficient treatment in the market, making this disease an unmet clinical need.The aggressivity of TNBC is due to the easiness of its metastization expanding...</teaser>
  <objective>R-nuucell is developing a new drug to treat Triple Negative Breast Cancer (TNBC) for which there is not any specific and efficient treatment in the market, making this disease an unmet clinical need.
The aggressivity of TNBC is due to the easiness of its metastization expanding the cancer through the body inevitably leading to death. So far, we gathered a set of results showing the antimetastatic potential of our new drug which mode of action would, conceptually, be able to eliminate the deadliest feature of cancer cells – their ability to invade and metastasize. This happens because the target of our drug is the cells’ foundation (ie the cytoskeleton). Thus, destroying the cytoskeleton of cells is like shaking the foundations of a house, it will be tumble-down!
With the Women TechEU program we will consolidate the proof-of-concept of the drug’s efficiency against metastases through two sets of in vivo studies in nude mice, and we will start the pre-clinical studies by performing pharmacokinetics (drug absorption, distribution, metabolism and excretion). Also, in view of the natural future development of our drug we will start to develop its synthesis scale-up from the milligram to the multigram scale. 
Women TechEU program mentoring and coaching will be also key to consolidate our business plan and to approach partners and investors towards a fundraising Level A in the near future. This level of funding (~1 M€) will enable to finish our pre-clinical studies and place R-nuucell in the position to license its international patent, one of the company’s assets (PT108082B, EA038640B1, EP3227307B1, CN107466297B, JP6726678B2, US15/533,289, under examination on Canada, Brazil and India), to a pharmaceutical company using a “business-to-business” strategy.</objective>
  <title>A NEW DRUG TO TREAT TRIPLE NEGATIVE BREAST CANCER</title>
  <totalCost>0</totalCost>
  <ecMaxContribution>75000</ecMaxContribution>
  <startDate>2022-06-01</startDate>
  <endDate>2023-05-31</endDate>
  <ecSignatureDate>2022-05-24</ecSignatureDate>
  <duration>12</duration>
  <status>CLOSED</status>
  <keywords>metastatic cancer,  ruthenium drug,  targeted therapy</keywords>
  <identifiers>
    <grantDoi>10.3030/101071749</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2022-06-17 10:31:42</sourceUpdateDate>
  <contentCreationDate>2022-08-10 17:33:13</contentCreationDate>
  <contentUpdateDate>2025-09-01 22:53:50</contentUpdateDate>
  <lastUpdateDate>2025-09-19 14:48:51</lastUpdateDate>
  <relations>
    <associations>
      <article source="editorial" type="relatedArticle">
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <rcn>436715</rcn>
        <id>436715-a-novel-anti-metastatic-treatment-against-triple-negative-breast-cancer</id>
        <title>A novel anti-metastatic treatment against triple negative breast cancer</title>
        <contentUpdateDate>2022-10-31 17:44:07</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/projectDescription</code>
              <title>Project description</title>
              <description>Article: description of linked project written by editorial team</description>
              <displayCode>/Project description</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/editorial</code>
              <title>CORDIS Editorial</title>
              <description>Written by CORDIS</description>
              <displayCode>/CORDIS Editorial</displayCode>
            </category>
          </categories>
        </relations>
      </article>
      <article source="editorial" type="relatedArticle">
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <rcn>446734</rcn>
        <id>446734-novel-drug-offers-hope-in-battle-against-breast-cancer</id>
        <title>Novel drug offers hope in battle against breast cancer</title>
        <contentUpdateDate>2023-10-06 14:39:45</contentUpdateDate>
        <relations>
          <associations>
            <webItem type="relatedImage" source="editorial" represents="article">
              <language>any</language>
              <availableLanguages>any</availableLanguages>
              <uri>/docs/article/images/2023-10/446734.jpg</uri>
              <mimetype>image/jpeg</mimetype>
              <size>116834</size>
            </webItem>
          </associations>
          <categories>
            <category classification="applicationDomain" type="isApplicableIn">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/health</code>
              <title>Health</title>
              <displayCode>/Health</displayCode>
            </category>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/brief</code>
              <title>Result in Brief</title>
              <description>Article: Classic and enhanced</description>
              <displayCode>/Result in Brief</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/editorial</code>
              <title>CORDIS Editorial</title>
              <description>Written by CORDIS</description>
              <displayCode>/CORDIS Editorial</displayCode>
            </category>
          </categories>
        </relations>
        <teaser>Promising results of a new ‘metallodrug’ could lead to an effective new treatment against a particularly aggressive form of breast cancer.</teaser>
      </article>
      <call source="corda" type="relatedMasterCall">
        <rcn>55405</rcn>
        <title>HORIZON-EIE-2021-SCALEUP-01</title>
        <identifier>HORIZON-EIE-2021-SCALEUP-01</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>55405</rcn>
        <title>HORIZON-EIE-2021-SCALEUP-01</title>
        <identifier>HORIZON-EIE-2021-SCALEUP-01</identifier>
      </call>
      <organization netEcContribution="75000" totalCost="0" source="corda" order="1" ecContribution="75000" terminated="false" sme="true" type="coordinator">
        <availableLanguages>en</availableLanguages>
        <rcn>1975338</rcn>
        <id>888729812</id>
        <vatNumber>PT516289292</vatNumber>
        <legalName>SOMETHING IN HANDS - INVESTIGACAOCIENTIFICA, LDA</legalName>
        <address>
          <street>EDIFICIO TEC LABS, CAMPUS DA FCUL</street>
          <city>Lisboa</city>
          <postalCode>1749-016</postalCode>
          <country>PT</country>
          <geolocation>38.7051749,-9.2306212</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/PRC</code>
              <title>Private for-profit entities (excluding Higher or Secondary Education Establishments)</title>
              <displayCode>/Private for-profit entities (excluding Higher or Secondary Education Establishments)</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Portugal</name>
              <rcn>427199016</rcn>
              <nutsCode>PT</nutsCode>
              <euCode>PT</euCode>
              <isoCode>PT</isoCode>
            </region>
            <region type="relatedRegion">
              <name>Portugal</name>
              <rcn>427199016</rcn>
              <nutsCode>PT</nutsCode>
              <euCode>PT</euCode>
              <isoCode>PT</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme type="relatedLegalBasis" source="corda" uniqueProgrammePart="true">
        <availableLanguages>en</availableLanguages>
        <rcn>705796</rcn>
        <id>HORIZON.3.2</id>
        <code>HORIZON.3.2</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.3.2</pga>
        <title>European innovation ecosystems</title>
        <parent>
          <programme>
            <rcn>705791</rcn>
            <code>HORIZON.3</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode>/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme type="relatedTopic" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>706035</rcn>
        <id>HORIZON_HORIZON-EIE-2021-SCALEUP-01-03</id>
        <code>HORIZON-EIE-2021-SCALEUP-01-03</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>Women TechEU</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode>/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43454386</code>
              <title>Market-creating innovation</title>
              <displayCode>/Market-creating innovation</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43453573</code>
              <title>Innovation and diversity (e.g. gender)</title>
              <displayCode>/Innovation and diversity (e.g. gender)</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43453477</code>
              <title>Industrial dynamics</title>
              <displayCode>/Industrial dynamics</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43453576</code>
              <title>Innovation management</title>
              <displayCode>/Innovation management</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43452634</code>
              <title>Gender in innovation development</title>
              <displayCode>/Gender in innovation development</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43452100</code>
              <title>Financial &amp; Investment management</title>
              <displayCode>/Financial &amp; Investment management</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43454392</code>
              <title>Marketing management</title>
              <displayCode>/Marketing management</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43458202</code>
              <title>Technology management</title>
              <displayCode>/Technology management</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43450026</code>
              <title>Business management</title>
              <displayCode>/Business management</displayCode>
            </category>
            <category classification="topicKeyword" type="isAbout">
              <language>en</language>
              <availableLanguages>en</availableLanguages>
              <code>/43453837</code>
              <title>IPR management</title>
              <displayCode>/IPR management</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>977166</rcn>
        <id>101071749_PSHORIZON</id>
        <title>Periodic Reporting for period 1 - CanceRusolution (A NEW DRUG TO TREAT TRIPLE NEGATIVE BREAST CANCER)</title>
        <description>periodic</description>
        <teaser>Survival rates for patients with Triple Negative Breast Cancer (TNBC) are as low as 11%. This type of breast cancer is more aggressive and with a poor prognosis since, at a very early stage, it develops metastases, i.e., secondary tumors in other organs. While patients with...</teaser>
        <sourceUpdateDate>2023-09-04 19:59:11</sourceUpdateDate>
        <contentUpdateDate>2023-09-29 15:41:57</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/pubsum</code>
              <title>Report Summary</title>
              <description>Result: Publishable summary (FP7 SESAM) and Summary for publication (H2020 SyGMa)</description>
              <displayCode>/Report Summary</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1237407</rcn>
        <id>101071749_F683506EFC93E284957D109420BF3366_IPRHORIZON</id>
        <title>MACROMOLECULAR TRANSITION METAL COMPLEXES FOR TREATMENT OF CANCER AND PROCESS FOR THEIR PREPARATION</title>
        <details>
          <iprAwarded>EP</iprAwarded>
          <iprNumber>15820592</iprNumber>
          <iprDate>2015-12-07</iprDate>
          <iprPrefix>EP</iprPrefix>
        </details>
        <sourceUpdateDate>2025-01-10 11:51:31</sourceUpdateDate>
        <contentUpdateDate>2025-01-10 11:51:31</contentUpdateDate>
        <relations>
          <associations>
            <organization source="corda" type="isRegisteredBy">
              <availableLanguages>en</availableLanguages>
              <rcn>1975338</rcn>
              <id>888729812</id>
              <vatNumber>PT516289292</vatNumber>
              <legalName>SOMETHING IN HANDS - INVESTIGACAOCIENTIFICA, LDA</legalName>
              <address>
                <street>EDIFICIO TEC LABS, CAMPUS DA FCUL</street>
                <city>Lisboa</city>
                <postalCode>1749-016</postalCode>
                <country>PT</country>
                <geolocation>38.7051749,-9.2306212</geolocation>
              </address>
              <relations>
                <categories>
                  <category classification="organizationActivityType" type="relatedOrganizationActivityType">
                    <language>en</language>
                    <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
                    <code>/PRC</code>
                    <title>Private for-profit entities (excluding Higher or Secondary Education Establishments)</title>
                    <displayCode>/Private for-profit entities (excluding Higher or Secondary Education Establishments)</displayCode>
                  </category>
                </categories>
                <regions>
                  <region type="relatedNutsCode">
                    <name>Portugal</name>
                    <rcn>427199016</rcn>
                    <nutsCode>PT</nutsCode>
                    <euCode>PT</euCode>
                    <isoCode>PT</isoCode>
                  </region>
                  <region type="relatedRegion">
                    <name>Portugal</name>
                    <rcn>427199016</rcn>
                    <nutsCode>PT</nutsCode>
                    <euCode>PT</euCode>
                    <isoCode>PT</isoCode>
                  </region>
                </regions>
              </relations>
            </organization>
          </associations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/ipr</code>
              <title>Intellectual Property Rights</title>
              <description>Result: Intellectual property rights linked to the results of EU funded research (FP7 onwards)</description>
              <displayCode>/Intellectual Property Rights</displayCode>
            </category>
            <category classification="iprType" type="isRegisteredAs">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/PATENT</code>
              <title>Patent</title>
              <displayCode>/Patent</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode>/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/35/159/647</code>
        <title>pharmacokinetics</title>
        <displayCode>/medical and health sciences/basic medicine/pharmacology and pharmacy/pharmacokinetics</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode>/Digital agenda</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode>/Clean air</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode>/Artificial intelligence</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode>/Climate action</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode>/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages>en</availableLanguages>
        <code>/HORIZON-CSA</code>
        <title>HORIZON Coordination and Support Actions</title>
        <description>HORIZON Coordination and Support Actions</description>
        <displayCode>/HORIZON Coordination and Support Actions</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode>/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>